Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fibromun + Doxorubicin in Advanced Solid Tumors
NCT02076620Phase 1Completed
- Sponsor
- Philogen
- Start
- Jan 2013
- Primary completion
- Jan 2018
- Modality
- Antibody Fragments, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of onfekafusp alfa in solid tumor, sponsored by Philogen. Primary endpoint: Dose Limiting Toxicity. Started Jan 2013; status: completed.
02
Drugs
onfekafusp alfa
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02076620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02076620.